Advertisement
Advertisement
BRTX
BioRestorative Therapies, Inc. Common Stock (NV)
0.20
USDSponsored
0.00
-1.47%
Aug 10, 15:59 UTC -4
Closed
After-Market
0.21
+0.01
+2.99%
BRTX Earnings Reports
Positive Surprise Ratio
BRTX beat 14 of 17 last estimates.
82%
Next Report
Today
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$341.70K
/-$0.12
Implied change from Q1 26 (Revenue/ EPS)
+1385.65%
/--
Implied change from Q2 25 (Revenue/ EPS)
+12.77%
/-60.00%
BioRestorative Therapies, Inc. Common Stock (NV) earnings per share and revenue
On May 14, 2026, BRTX reported earnings of -0.12 USD per share (EPS) for Q1 26, beating the estimate of -0.20 USD, resulting in a 41.18% surprise. Revenue reached 23.00 thousand, compared to an expected 318.75 thousand, with a -92.78% difference. The market reacted with a +1.75% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 341.70 thousand USD, implying an increase of 0.00% EPS, and increase of 1385.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were BioRestorative Therapies, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, BioRestorative Therapies, Inc. Common Stock (NV) reported EPS of -$0.12, beating estimates by 41.18%, and revenue of $23.00K, -92.78% below expectations.
How did the market react to BioRestorative Therapies, Inc. Common Stock (NV)'s Q1 2026 earnings?
The stock price moved up 1.75%, changed from $0.19 before the earnings release to $0.19 the day after.
When is BioRestorative Therapies, Inc. Common Stock (NV) expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for BioRestorative Therapies, Inc. Common Stock (NV)'s next earnings report?
Based on 3
analysts, BioRestorative Therapies, Inc. Common Stock (NV) is expected to report EPS of -$0.12 and revenue of $341.70K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement